Trial Profile
Phase II trial in Japan of PLX PAD in patients with critical limb ischaemia.
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 04 Apr 2023
Price :
$35
*
At a glance
- Drugs Emiplacel (Primary)
- Indications Chronic limb-threatening ischemia
- Focus Adverse reactions; Therapeutic Use
- 13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
- 10 May 2016 According to a Pluristem media release, the company anticipates that data from this trial will lead to conditional marketing approval for PLX-PAD in the treatment of Critical Limb Ischemia in Japan.
- 10 May 2016 According to Pluristem media release, Japan's Pharmaceuticals and Medical Devices Agency has cleared the protocol for this trial.